Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Ravulizumab in Adult Patients With Proliferative Lupus Nephritis or IgA Nephropathy
2020-001537-13Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and IgA nephropathy (IgAN) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Percentage change in proteinuria. Started Dec 2020; status: active.
02
Drugs
ravulizumab
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-001537-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001537-13.